Table 5.
Means and standard errors for primary outcomes as a function of treatment condition and time
| Outcome | Condition | Time 1 | Time 2 | Time 3 |
|---|---|---|---|---|
| M (SE) | M (SE) | M (SE) | ||
| FACT-G PWBab | CBSM | 23.26 (0.39) | 23.16 (0.40) | 23.29 (0.41) |
| HP | 23.09 (0.39) | 22.99 (0.40) | 23.11 (0.41) | |
| FACT-G SWBcde | CBSM | 19.85 (0.42) | 20.61 (0.43) | 20.74 (0.44) |
| HP | 21.16 (0.43) | 21.91 (0.44) | 22.05 (0.45) | |
| FACT-G EWBad | CBSM | 20.03 (0.39) | 20.18 (0.39) | 19.20 (0.40) |
| HP | 20.46 (0.38) | 20.62 (0.39) | 20.43 (0.39) | |
| FACT-G FWBb | CBSM | 20.27 (0.48) | 20.49 (0.49) | 20.08 (0.50) |
| HP | 20.48 (0.47) | 20.70 (0.48) | 20.29 (0.49) | |
| EPIC urinary botherb | CBSM | 75.90 (1.75) | 77.60 (1.78) | 77.25 (1.81) |
| HP | 74.25 (1.73) | 75.95 (1.76) | 75.60 (1.79) | |
| EPIC urinary functioncfg | CBSM | 84.30 (1.82) | 85.28 (1.81) | 85.38 (1.83) |
| HP | 79.97 (1.79) | 80.95 (1.79) | 81.05 (1.81) | |
| EPIC sexual bothera | CBSM | 52.79 (3.63) | 53.23 (3.75) | 52.57 (3.81) |
| HP | 58.67 (3.65) | 59.12 (3.77) | 58.45 (3.87) | |
| EPIC sexual functionacdhj | CBSM | 12.07 (1.69) | 8.50 (1.65) | 8.11 (1.75) |
| HP | 15.82 (1.71) | 12.25 (1.66) | 11.86 (1.76) | |
| PROMIS depressionabdh | CBSM | 46.42 (0.84) | 46.78 (0.82) | 47.03 (0.86) |
| HP | 45.78 (0.84) | 46.13 (0.81) | 46.38 (0.85) | |
| FSIb | CBSM | 9.62 (1.19) | 9.61 (1.22) | 10.12 (1.24) |
| HP | 8.42 (1.18) | 8.41 (1.20) | 8.92 (1.23) | |
| MPQab | CBSM | 5.50 (0.62) | 4.69 (0.63) | 4.96 (0.65) |
| HP | 6.24 (0.61) | 5.43 (0.63) | 5.70 (0.64) |
CBSM, cognitive-behavioral stress management; HP, health promotion; FACT, Functional Assessment of Cancer Therapy; PWB, physical well-being; SWB, social well-being; EWB, emotional well-being; FWB, functional well- being; EPIC, Expanded Prostate Cancer Index; PROMIS, Patient-Reported Outcomes Measurement Information System; FSI, Fatigue Symptom Inventory; MPQ, McGill Pain Questionnaire. Means and standard errors are computed at the means for the covariates significantly associated with each outcome. Covariates adjusted for in each analysis included the following:
age,
comorbidity index,
marital status,
race,
family annual income,
group stratification,
days from session 10 to time 2,
prostate cancer treatment history at each timepoint,
years since diagnosis,